Trial analysis
4indications covered
Mine the trials
We analyzed clinical trial data with AI-driven tools across all four indications of interest.
Case Study · Biomarker Landscape
Choosing biomarkers for IL-17 trials.
A biotech with a best-in-class IL-17 inhibitor needed biomarkers to track disease progression in its trials. We combined trial data, literature, AI-driven analysis and expert interviews to identify 153 biomarkers and recommend panels for each indication.
The Client
The client is a biotech company developing a best-in-class IL-17 inhibitor for autoimmune conditions. It wanted to choose biomarkers that would strengthen its clinical trials.
The Challenge
Four indications.
Pick the right markers.
Prescouter was asked to identify biomarkers for monitoring disease progression in IL-17 inhibitor trials across psoriatic arthritis, uveitis, hidradenitis suppurativa and enthesitis, as late-stage demands keep rising.
-
Indications
Four autoimmune targets
Arthritis, uveitis, skin and enthesitis.
-
Evidence
Established and emerging
Covering proven and novel markers.
-
Practicality
Panels and matrices
Which samples and tests to use.
Our Approach
Building a biomarker landscape from four sources.
Literature review
153biomarkers identified
Map the evidence
We reviewed the literature to capture both established and emerging biomarkers in each domain.
Expert interviews
Vettedreadiness insights
Test the readiness
Experts weighed in on readiness, reliability and expected challenges for each biomarker.
The Outcome
Biomarker panels ready for the clinic.
Prescouter identified 153 biomarkers across all areas of interest and recommended biomarker panels, sample matrices and testing methods for each domain. Expert insights on readiness, reliability and challenges gave the client a clear view of how ready biomarkers are for its trials.
-
Landscape
153 biomarkers
Established and emerging, in four indications.
-
Panels
Per-indication recommendations
Panels, sample matrices and test methods.
-
Readiness
Expert-vetted insight
Reliability and challenges for each option.
Late-stage trials ask more of biomarkers than ever. Choosing them early, with evidence and expert input, keeps a program on track.
Let’s Talk
Which biomarkers could strengthen your trials?
Map the evidence, test it with experts and build panels that fit each indication. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]